Dashboard
Portfolios
Watchlist
Community
Discover
Screener
AN
AnalystHighTarget
Community Contributor
Followers
2
Total number of followers
Comments
0
Total number of comments
Member Since
2025
Date joined
No bio added yet
No link added
Blackstone
AN
AnalystHighTarget
Consensus Narrative from 20 Analysts
BIP Expansion And Global Wealth Will Create New Opportunities
Key Takeaways Blackstone's infrastructure and private wealth strategies drive strong revenue growth, supported by successful geographic expansion and fundraising efforts. Real estate recovery and credit business momentum are expected to boost earnings, driven by strategic sector positioning and innovation.
View narrative
US$204.06
FV
38.7% undervalued
intrinsic discount
20.44%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Texas Instruments
AN
AnalystHighTarget
Consensus Narrative from 29 Analysts
Expanding 300-Millimeter Capacity Will Shape The Semiconductor Landscape
Key Takeaways Strategic investment in manufacturing capabilities is expected to bolster revenue growth and profitability through efficient demand fulfillment and reduced production costs. Increasing focus on industrial and automotive markets, along with strong China performance, is expected to drive significant revenue and earnings growth.
View narrative
US$238.26
FV
36.5% undervalued
intrinsic discount
17.12%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
American Express
AN
AnalystHighTarget
Consensus Narrative from 24 Analysts
Expanding Merchant Network And Millennial Focus Will Succeed
Key Takeaways Focus on global merchant network expansion and targeting of younger generations drives revenue growth through increased transaction volumes and premium product adoption. Strong product innovation and SME investment support growth in margins and earnings, with robust credit performance ensuring financial resilience.
View narrative
US$348.00
FV
32.8% undervalued
intrinsic discount
11.85%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Pfizer
AN
AnalystHighTarget
Consensus Narrative from 21 Analysts
Oncology Integration And Phase III Trials Will Redefine Future
Key Takeaways Pfizer's oncology focus strengthens its portfolio and future revenue through Seagen integration and promising R&D pipeline developments in oncology and vaccines. Operational efficiency, AI-driven marketing strategies, and strategic capital deployment aim to boost margins, earnings, and shareholder value while optimizing resources and reducing costs.
View narrative
US$35.58
FV
35.4% undervalued
intrinsic discount
1.74%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
New
narrative